Oculus Innovative Sciences (OCLS) Misses Q1 EPS by 5c
Get Alerts OCLS Hot Sheet
Join SI Premium – FREE
Oculus Innovative Sciences (NASDAQ: OCLS) reported Q1 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.96 million.
"In late 2014, after making a strategic decision to enter the dermatology market directly, we deployed a direct U.S. sales force and launched four prescription dermatology products. We are pleased to see that the benefits of expanding our presence in the dermatology market, with its strong pricing reimbursement and quick sales ramps, has resulted in significant sales growth in the United States over the last six months," said Oculus' CEO Jim Schutz. "We believe the growth in dermatology sales will continue as we launch new products, grow our existing product lines and hire additional sales people."
For earnings history and earnings-related data on Oculus Innovative Sciences (OCLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Knight-Swift Transportation (KNX) Lowers Guidance
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!